万邦医药(301520.SZ)：上半年净利润2681.14万元 同比下降51.28%

Core Insights - Wanbang Pharmaceutical (301520.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved a revenue of 147 million yuan, representing a year-on-year decrease of 21.57% [1] - The net profit attributable to shareholders was 26.81 million yuan, down 51.28% compared to the previous year [1] - The net profit after deducting non-recurring gains and losses was 12.33 million yuan, reflecting a substantial decline of 70.17% year-on-year [1] - Basic earnings per share stood at 0.40 yuan [1]